Appointment dossier — Fallopian Tube Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Fallopian Tube Cancer
- Bevacizumab — Human evidence · 2 positive · PMID 38872480, 22529265
- Olaparib — Human evidence · 2 positive · PMID 37592269, 33743851
- Relacorilant — Human evidence · 2 positive / 1 negative-mixed · PMID 42334771, 40473448, 39032926, 37364223
- Mirvetuximab Soravtansine — Human evidence · 0 positive / 1 negative-mixed · PMID 30379722
- Nivolumab †Rx — Human evidence · 0 positive · PMID 34593565
- Rucaparib — Human evidence · 0 positive · PMID 34593565
- Carboplatin — Review evidence · 1 positive · PMID 37592269
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
- Paclitaxel — Review evidence · 1 positive / 1 negative-mixed · PMID 37592269, 10985612
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05659381 · Phase 3 — Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer (United States)
- NCT04575935 · Phase 3 — Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial (United States)
- NCT07743164 · Phase 3 — A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) (United States)
- NCT05281471 · Phase 3 — Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (United States)
- NCT03564340 · Phase 1 / Phase 2 — Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (United States)
- NCT05200260 · Phase 2 — Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer (China)
- NCT05460000 · Phase 2 — A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (Austria)
- NCT05080556 · Phase 2 — Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer (United Kingdom)
- NCT07402915 · Phase 1 — Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Georgia)
- NCT06469281 · Phase 1 — A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers (United States)
- NCT05429970 — A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) (United States)
- NCT05912972 — Development and Management of Registry in Patients With Gynecologic Cancer in Korea (South Korea)
- NCT00005095 — Specimen and Data Study for Ovarian Cancer Early Detection and Prevention (United States)
- NCT04196257 · Phase 1 — BP1001-A in Patients With Advanced or Recurrent Solid Tumors (United States)
- NCT07213804 · Phase 3 — A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer (United States)
- NCT06828354 · Phase 3 — A Study of SHR-A1811 in Subjects With Ovarian Cancer (China)
- NCT04520074 · Phase 3 — Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) (China)
- NCT07617753 · Phase 1 / Phase 2 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 (China)
Most-relevant first: trials that name Fallopian Tube Cancer, then broader trials you may still qualify for. 123 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
- Nivolumab †Rx × Ipilimumab — Synergize (moderate)
- Nivolumab †Rx × corticosteroids — Use For IrAE (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Bevacizumab has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that Olaparib has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that Relacorilant has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05659381), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?